Clinical trials: Vaccination; Sepsis

Toxic Shock Syndrome, Vaccination; Sepsis

rTSST-1 Variant Vaccine Phase 1 First-in-man Trail

• Completed
• Age: 18 to 64 years
• Phase 1
• Vaccines
• Injection or infusion
• Results posted

Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.

Trial name

rTSST-1 (NCT02340338)

Testing

rTSST-1 Variant Candidate Vaccine

Where

Austria

Volunteers

46 people, healthy volunteers welcome

Sponsor

Biomedizinische Forschungs gmbH